Friday, March 15, 2019 11:45:12 AM
it went up to 7.69
then dropped to 4.38
and on the 4th day... 73.52
Date Open High Low Close* Adj Close** Volume
Mar 15, 2019 27.50 31.99 27.49 30.10 30.10 1,403,507
Mar 14, 2019 28.11 30.86 27.00 27.47 27.47 1,750,600
Mar 13, 2019 35.34 36.25 31.02 31.05 31.05 2,495,200
Mar 12, 2019 30.78 39.88 28.15 35.13 35.13 11,140,600
Mar 11, 2019 22.98 38.00 22.00 32.44 32.44 11,674,500
Mar 08, 2019 33.85 35.86 21.00 21.00 21.00 5,340,000
Mar 07, 2019 18.20 73.52 17.01 38.86 38.86 36,079,200
Mar 06, 2019 7.45 14.60 6.91 12.02 12.02 72,385,800
Mar 05, 2019 5.20 5.23 4.38 4.62 4.62 1,951,100
Mar 04, 2019 6.80 7.69 5.40 5.50 5.50 7,718,200
Mar 01, 2019 2.65 8.84 2.65 7.72 7.72 58,812,200
Feb 28, 2019 2.00 2.73 1.98 2.60 2.60 1,291,800
Recent ATOS News
- Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen • GlobeNewswire Inc. • 04/29/2024 12:30:00 PM
- Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer • GlobeNewswire Inc. • 04/15/2024 12:30:00 PM
- Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference • GlobeNewswire Inc. • 04/11/2024 12:30:00 PM
- Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen • GlobeNewswire Inc. • 04/09/2024 03:59:00 PM
- Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/01/2024 08:00:00 PM
- Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements • GlobeNewswire Inc. • 03/18/2024 12:30:00 PM
- Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors • GlobeNewswire Inc. • 03/12/2024 12:30:00 PM
- Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study • GlobeNewswire Inc. • 02/22/2024 01:30:00 PM
- Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial • GlobeNewswire Inc. • 02/07/2024 01:30:00 PM
- Atossa Therapeutics Issues Letter to Shareholders • GlobeNewswire Inc. • 01/09/2024 01:30:00 PM
- Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director • GlobeNewswire Inc. • 12/04/2023 01:30:00 PM
- Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial • GlobeNewswire Inc. • 11/20/2023 01:30:00 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/15/2023 10:03:55 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 09:05:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 02:10:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:00:13 PM
- Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/13/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 02:00:40 PM
- Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors • GlobeNewswire Inc. • 11/09/2023 02:00:00 PM
- Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group • PR Newswire (US) • 10/30/2023 05:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 08:00:20 PM
- Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later • PR Newswire (US) • 10/11/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 08:00:30 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM